



# CLINICAL TRIALS OF TEXAS, INC.

*Promoting Health Through Research*

---

## Curriculum Vitae

### Amy Edmondson Mulroy, MD

---

7940 Floyd Curl Drive, Suite 700  
San Antonio, Texas 78229

7940 Floyd Curl Drive, Suite 1020  
San Antonio, Texas 78229

#### EDUCATION

- 1997 General Adult Psychiatry Internship and Residency, University of Texas Health Science Center, San Antonio, Texas  
1993 Doctor of Medicine, University of Texas Medical School, San Antonio, Texas  
1989 Bachelor of Science in Microbiology, Texas A&M University, College Station, Texas

#### LICENSE(S)

- 1994 Texas Medical Board, # J6417

#### CERTIFICATION(S)

- 1998 American Board of P&N/Psychiatry

#### PROFESSIONAL EXPERIENCE

- 2001-Present Private practice in the treatment of psychiatric illnesses, San Antonio, Texas  
▪ Focus in adult patients with MDD, GAD, Panic Disorders, Bipolar I and II, dementia-related illnesses  
1997-2001 Clinical Assistant Professor, University of Texas Health Science Center at San Antonio, San Antonio, Texas  
▪ Attending physician at University Health System-Mood Disorder Clinic  
▪ Psychotherapy advisor for psychiatric residents

#### PROFESSIONAL MEMBERSHIP(S)

- 1998-Present Diplomat, American Board of Psychiatry and Neurology  
1996-1997 Texas Society of Psychiatric Physicians  
1993-Present Bexar County Psychiatric Society  
1993-Present Texas Society of Psychiatric Physicians  
1992-Present American Psychiatric Association  
1992-Present Alpha Omega Alpha Medical Honor Society  
1989-Present Bexar County Medical Society  
1989-Present Texas Medical Association

#### HOSPITAL AFFILIATION(S)

NIX Health System, San Antonio, Texas

#### RESEARCH AFFILIATION(S)

- 2003-Present Investigator, Clinical Trials of Texas, Inc., San Antonio, Texas

1997-2001 Sub-Investigator with Donald Royall, MD, University of Texas Health Science Center at San Antonio, San Antonio, Texas

## RESEARCH EXPERIENCE

2010-Present: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of "Study Drug" As Adjunctive Therapy In The Treatment Of Adults With Major Depressive Disorder (CTT-000217)

2010-Present: A Phase 2, Multicenter, Open-Label Study To Assess The Safety And Tolerability Of Oral "Study Drug" As Adjunctive Therapy In Adult Patients With Major Depressive Disorder (CTT-000228)

2009-Present: A Randomized Controlled Trial To Assess The Efficacy Of A Medical Food In Patients With Mild To Moderate Alzheimer's Disease Using Alzheimer's Disease Medication (CTT-000174)

2009-Present: A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Trial Of "Study Drug" (100 Milligrams) Administered Orally Once Daily In Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder In The United States (CTT-000196)

2009-Present: A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Trial Of "Study Drug" (100 Milligrams) Administered Orally Once Daily In Premenopausal Women With Hypoactive Sexual Desire Disorder In The United States (CTT-000197)

2009-Present: A Double-Blind, Placebo-Controlled, Flexible-Dose Study Of "Study Drug" In Patients With Major Depressive Disorder (CTT-000207)

2009-Present: A Long-Term, Open-Label Extension Study Of "Study Drug" In Adult Patients With Major Depressive Disorder (CTT-000212)

2009-Present: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase III Safety Trial Of "Study Drug" (100 Milligrams Daily) In Women Taking A Selective Serotonin Or Serotonin-Norepinephrine Reuptake Inhibitor With Decreased Sexual Desire And Distress (CTT-000213)

2009-2010: A Study Of Augmentation With "Study Drug" For Patients With Major Depressive Disorder Who Are Partial Responders To Selective Serotonin Reuptake Inhibitor Treatment (CTT-000157)

2009-2009: A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy And Safety Study Of "Study Drug" In The Treatment Of Generalized Anxiety Disorder (GAD) (CTT-000154)

2008-2009: Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study Of "Study Drug" In The Treatment Of Depression In Patients With Bipolar I Or II Disorder (CTT-000156)

2008-2009: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing The Efficacy And Safety Of 2 Doses Of "Study Drug" In Acute Treatment Of Adults With Generalized Anxiety Disorder (CTT-000122)

2008-2009: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing The Efficacy And Safety Of "Study Drug" Versus Placebo In Acute Treatment Of Adults With Major Depressive Disorder (CTT-000119)

2007-2008: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Of The Efficacy And Safety Of "Study Drug" Compared With Placebo As An Adjunct To Treatment In Patients With Generalized Anxiety Disorder Who Demonstrate Partial Or No Response To A Selective Serotonin Reuptake Inhibitor Or Serotonin-Norepinephrine Reuptake Inhibitor Alone Or In Combination With A Benzodiazepine (CTT-000096)

2007-2008 A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study Of The Efficacy And Safety Of "Study Drug" As Mono-Therapy In The Treatment Of Elderly Patients With Major Depressive Disorder (Sapphire Study) (CTT-000076)

2007-2008 A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study Of The Efficacy And Safety Of "Study Drug" As Mono-Therapy In The Treatment Of Elderly Patients With Generalized Anxiety Disorder (Chromium Study) (CTT-000077)

2007-2008: A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral "Study Drug" In Outpatients With Bipolar I Depression (CTT-000099)

2006-2008: A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study Of The Efficacy And Safety Of "Study Drug" As Monotherapy In The Maintenance Treatment Of Patients With Generalized Anxiety Disorder Following An Open-Label Stabilisation Period (Amethyst Study) (CTT-000024)

2006-2007: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study Of The Efficacy And Safety Of "Study Drug" As Mono-Therapy In The Treatment Of Adult Patients With Major Depressive Disorder (CTT-000065)

2006-2007: 26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral "Study Drug" In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)

2006-2007: Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral "Study Drug" In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (CTT-000054)

2006-2008: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study Of The Efficacy And Safety Of "Study Drug" In Combination With An Antidepressant In The Treatment Of Patients With Major Depressive Disorder With Inadequate Response To An Antidepressant Treatment (Pearl Study) (CTT-000038)

2005-2007: A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study Of The Efficacy And Safety Of "Study Drug" As Monotherapy In The Maintenance Treatment Of Patients With Major Depressive Disorder Following An Open-Label Stabilization Period

2005-2006: A 12 Week, Multi-Center, Open Label Study To Evaluate The Effectiveness And Safety Of "Study Drug" In Hispanic Patients With Mild To Moderate Alzheimer's Disease

2004-2005: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study To Evaluate The Efficacy, Safety And Tolerability Of "Study Drug" In Elderly Subjects With Major Depressive Disorder

2004-2005: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess The Safety, Tolerability, And Efficacy Of "Study Drug" And Treatment With "Study Drug" In Subjects With Mild Cognitive Impairment (MCI)

2003-2004: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison Of The Effects On Sexual Functioning Of "Study Drug" In Outpatients With Moderate To Severe Major Depression Over An Eight-Week Treatment Period

2003-2004: A Study Of "Study Drug" Versus "Study Drug" And Placebo In The Treatment Of Patients With Major Depression

*Previous Research Experience*

2000: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation Of The Efficacy And Safety Of "Study Drug" In The Patients With Dementia Associated With Cerebrovascular Disease

2000: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation Of The Efficacy And Safety Of "Study Drug" In The Patients With Early Alzheimer's Disease

2000: The Efficacy, Safety, And Tolerability Of "Study Drug" Versus Placebo, Administered For One Year In Patients With Probable Alzheimer's Disease

1999: "Study Drug" Versus Placebo In The Treatment Of Psychosis And Behavioral Disturbances Associated With Alzheimer's Disease

1999: A Twenty Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study Of The Efficacy, Tolerability And Safety Of "Study Drug" In The Treatment Of The Behavioral Manifestation Of Alzheimer's Disease In Outpatients Treated With "Study Drug"

1998: "Metrifonate Investigational Nationwide Trial, M.I.N.T."

1998: A Multicenter, Double-Blind Comparison Of Efficacy And Safety Of "Study Drug," "Study Drug," And Placebo In The Treatment Of Elderly Subjects Residing In Nursing Homes Or Assisted Care Facilities And Presenting With Alzheimer's Disease And Psychoses Or Other Selected Psychoses

1997: A Double-Blind, Placebo-Controlled Study Of "Study Drug" In The Treatment Of Signs And Symptoms Of Mania In Elderly Patients With Dementia

1997: An Open Label Extension Study Of "Study Drug" In The Treatment Of Signs And Symptoms Of Mania In Elderly Patients With Dementia

---

Signature and Date